A better resolution for integrating methods for monitoring Plasmodium falciparum resistance to antimalarial drugs

Acta Tropica

Volumn 137, Issue , 2014, Pages 44-57

  Abdul Ghani, Rashad ^a   Al Maktari, Mohamed T ^a   Al Shibani, Latifa A ^a   Allam, Amal F ^b  

^a SANA A UNIVERSITY   (Yemen)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Antimalarial drug resistance; In vitro assay; In vivo trial; Molecular marker; Plasmodium falciparum

Indexed keywords

AMODIAQUINE; ARTEMISININ; ARTESUNATE; CHLORPROGUANIL PLUS DAPSONE; MEFLOQUINE; MOLECULAR MARKER; PIPERAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT;

ANTIMALARIAL AGENT; BIOASSAY; BIOMARKER; BIOMONITORING; DISEASE CONTROL; DRUG RESISTANCE; EPIDEMIC; MALARIA; PARASITE;

ANTIMALARIAL DRUG RESISTANCE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG ELIMINATION; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; EX VIVO STUDY; GENOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; NONHUMAN; PARASITE ISOLATION; PARASITE TRANSMISSION; PARASITEMIA; PLASMA HALF LIFE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; DRUG EFFECTS; DRUG RESISTANCE; DRUG SENSITIVITY; EPIDEMIOLOGICAL MONITORING; GENETICS; MALARIA, FALCIPARUM; MOLECULAR DIAGNOSIS; PARASITOLOGY; PROCEDURES;

ANTIMALARIALS; DRUG RESISTANCE; EPIDEMIOLOGICAL MONITORING; HUMANS; MALARIA, FALCIPARUM; MOLECULAR DIAGNOSTIC TECHNIQUES; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM;

EID: 84901381290     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2014.04.031     Document Type: Review

References (232)

1. Abdel-Muhsin A.M., Ranford-Cartwright L.C., Medani A.R., Ahmed S., Suleiman S., Khan B., Hunt P., Walliker D., Babiker H.A. Detection of mutations in the Plasmodium falciparum dihydrofolate reductase (dhfr) gene by dot-blot hybridization. Am. J. Trop. Med. Hyg. 2002, 67:24-27.
2. Abdul-Ghani R., Farag H.F., Allam A.F. Sulfadoxine-pyrimethamine resistance in Plasmodium falciparum: a zoomed image at the molecular level within a geographic context. Acta Trop. 2013, 125:163-190.
3. Akala H.M., Eyase F.L., Cheruiyot A.C., Omondi A.A., Ogutu B.R., Waters N.C., Johnson J.D., Polhemus M.E., Schnabel D.C., Walsh D.S. Antimalarial drug sensitivity profile of western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay and molecular analysis. Am. J. Trop. Med. Hyg. 2011, 85:34-41.
4. Alifrangis M., Dalgaard M.B., Lusingu J.P., Vestergaard L.S., Staalsoe T., Jensen A.T., Enevold A., Ronn A.M., Khalil I.F., Warhurst D.C., Lemnge M.M., Theander T.G., Bygbjerg I.C. Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania. J. Infect. Dis. 2006, 193:1738-1741.
5. Alifrangis M., Enosse S., Pearce R., Drakeley C., Roper C., Khalil I.F., Nkya W.M., Ronn A.M., Theander T.G., Bygbjerg I.C. A simple, high-throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in the dihydrofolate reductase, dihydropteroate synthase, and P. falciparum chloroquine resistance transporter genes using polymerase chain reaction- and enzyme-linked immunosorbent assay-based technology. Am. J. Trop. Med. Hyg. 2005, 72:155-162.
6. Amaratunga C., Sreng S., Suon S., Phelps E.S., Stepniewska K., Lim P., Zhou C., Mao S., Anderson J.M., Lindegardh N., Jiang H., Song J., Su X.Z., White N.J., Dondorp A.M., Anderson T.J., Fay M.P., Mu J., Duong S., Fairhurst R.M. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect. Dis. 2012, 12:851-858.
7. Anderson T., Nkhoma S., Ecker A., Fidock D. How can we identify parasite genes that underlie antimalarial drug resistance?. Pharmacogenomics 2011, 12:59-85.
8. Anderson T.J., Haubold B., Williams J.T., Estrada-Franco J.G., Richardson L., Mollinedo R., Bockarie M., Mokili J., Mharakurwa S., French N., Whitworth J., Velez I.D., Brockman A.H., Nosten F., Ferreira M.U., Day K.P. Microsatellite markers reveal a spectrum of population structures in the malaria parasite Plasmodium falciparum. Mol. Biol. Evol. 2000, 17:1467-1482.
9. Anderson T.J., Nair S., Nkhoma S., Williams J.T., Imwong M., Yi P., Socheat D., Das D., Chotivanich K., Day N.P., White N.J., Dondorp A.M. High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J. Infect. Dis. 2010, 201:1326-1330.
10. Anderson T.J., Patel J., Ferdig M.T. Gene copy number and malaria biology. Trends Parasitol. 2009, 25:336-343.
11. Anderson T.J., Roper C. The origins and spread of antimalarial drug resistance: lessons for policy makers. Acta Trop. 2005, 94:269-280.
12. Andriantsoanirina V., Lascombes V., Ratsimbasoa A., Bouchier C., Hoffman J., Tichit M., Rabarijaona L.P., Durand R., Ménard D. Rapid detection of point mutations in Plasmodium falciparum genes associated with antimalarial drugs resistance by using high-resolution melting analysis. J. Microbiol. Methods 2009, 78:165-170.
13. Anthony T.G., Trueman H.E., Harbach R.E., Vogler A.P. Polymorphic microsatellite markers identified in individual Plasmodium falciparum oocysts from wild-caught Anopheles mosquitoes. Parasitology 2000, 121(Pt 2):121-126.
14. Ariey F., Witkowski B., Amaratunga C., Beghain J., Langlois A.C., Khim N., Kim S., Duru V., Bouchier C., Ma L., Lim P., Leang R., Duong S., Sreng S., Suon S., Chuor C.M., Bout D.M., Ménard S., Rogers W.O., Genton B., Fandeur T., Miotto O., Ringwald P., Le Bras J., Berry A., Barale J.C., Fairhurst R.M., Benoit-Vical F., Mercereau-Puijalon O., Ménard D. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014, 505:50-55.
15. Aubouy A., Bakary M., Keundjian A., Mbomat B., Makita J.R., Migot-Nabias F., Cot M., Le Bras J., Deloron P. Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. Antimicrob. Agents Chemother. 2003, 47:231-237.
16. Aubouy A., Mayombo J., Keundjian A., Bakary M., Le Bras J., Deloron P. Short report: lack of prediction of amodiaquine efficacy in treating Plasmodium falciparum malaria by in vitro tests. Am. J. Trop. Med. Hyg. 2004, 71:294-296.
17. Babiker H., Ranford-Cartwright L., Sultan A., Satti G., Walliker D. Genetic evidence that RI chloroquine resistance of Plasmodium falciparum is caused by recrudescence of resistant parasites. Trans. R. Soc. Trop. Med. Hyg. 1994, 88:328-331.
18. Bacon D.J., Latour C., Lucas C., Colina O., Ringwald P., Picot S. Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Antimicrob. Agents Chemother. 2007, 51:1172-1178.
19. Bacon D.J., Jambou R., Fandeur T., Le Bras J., Wongsrichanalai C., Fukuda M.M., Ringwald P., Sibley C.H., Kyle D.E. World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. Malaria J. 2007, 6:120.
20. Ballif M., Hii J., Marfurt J., Crameri A., Fafale A., Felger I., Beck H.P., Genton B. Monitoring of malaria parasite resistance to chloroquine and sulphadoxine-pyrimethamine in the Solomon Islands by DNA microarray technology. Malaria J. 2010, 9:270.
21. Barnes K.I., Lindegardh N., Ogundahunsi O., Olliaro P., Plowe C.V., Randrianarivelojosia M., Gbotosho G.O., Watkins W.M., Sibley C.H., White N.J. World Antimalarial Resistance Network (WARN) IV: clinical pharmacology. Malaria J. 2007, 6:122.
22. Barnes K.I., White N.J. Population biology and antimalarial resistance: the transmission of antimalarial drug resistance in Plasmodium falciparum. Acta Trop. 2005, 94:230-240.
23. Basco L., Ringwald P. Drug-resistant malaria: problems with its definition and technical approaches. Sante 2000, 10:47-50.
24. Basco L.K., Marquet F., Makler M.M., Le Bras J. Plasmodium falciparum and Plasmodium vivax: lactate dehydrogenase activity and its application for in vitro drug susceptibility assay. Exp. Parasitol. 1995, 80:260-271.
25. Bennett T.N., Paguio M., Gligorijevic B., Seudieu C., Kosar A.D., Davidson E., Roepe P.D. Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy. Antimicrob. Agents Chemother. 2004, 48:1807-1810.
26. Bin Dajem S.M., Al-Sheikh A.A., Bohol M.F., Alhawi M., Al-Ahdal M.N., Al-Qahtani A. Detecting mutations in PfCRT and PfMDR1 genes among Plasmodium falciparum isolates from Saudi Arabia by pyrosequencing. Parasitol. Res. 2011, 109:291-296.
27. Bjorkman A. Malaria associated anaemia, drug resistance and antimalarial combination therapy. Int. J. Parasitol. 2002, 32:1637-1643.
28. Bjorkman A., Bhattarai A. Public health impact of drug resistant Plasmodium falciparum malaria. Acta Trop. 2005, 94:163-169.
29. Bloland P. Drug Resistance in Malaria 2001, WHO, Geneva.
30. Bloland P.B., Ettling M. Making malaria-treatment policy in the face of drug resistance. Ann. Trop. Med. Parasitol. 1999, 93:5-23.
31. Borrmann S., Binder R.K., Adegnika A.A., Missinou M.A., Issifou S., Ramharter M., Wernsdorfer W.H., Kremsner P.G. Reassessment of the resistance of Plasmodium falciparum to chloroquine in Gabon: implications for the validity of tests in vitro vs. in vivo. Trans. R. Soc. Trop. Med. Hyg. 2002, 96:660-663.
32. Brasseur P., Agnamey P., Moreno A., Druilhe P. Evaluation of in vitro drug sensitivity of antimalarials for Plasmodium falciparum using a colorimetric assay (DELI-microtest). Méd. Ttrop. (Mars) 2001, 61:545-547.
33. Brockman A., Paul R.E., Anderson T.J., Hackford I., Phaiphun L., Looareesuwan S., Nosten F., Day K.P. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am. J. Trop. Med. Hyg. 1999, 60:14-21.
34. Brockman A., Singlam S., Phiaphun L., Looareesuwan S., White N.J., Nosten F. Field evaluation of a novel colorimetric method - double-site enzyme-linked lactate dehydrogenase immunodetection assay - to determine drug susceptibilities of Plasmodium falciparum clinical isolates from northwestern Thailand. Antimicrob. Agents Chemother. 2004, 48:1426-1429.
35. Brooks D.R., Wang P., Read M., Watkins W.M., Sims P.F., Hyde J.E. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem. 1994, 224:397-405.
36. Carnevale E.P., Kouri D., DaRe J.T., McNamara D.T., Mueller I., Zimmerman P.A. A multiplex ligase detection reaction-fluorescent microsphere assay for simultaneous detection of single nucleotide polymorphisms associated with Plasmodium falciparum drug resistance. J. Clin. Microbiol. 2007, 45:752-761.
37. Carrara V.I., Zwang J., Ashley E.A., Price R.N., Stepniewska K., Barends M., Brockman A., Anderson T., McGready R., Phaiphun L., Proux S., van Vugt M., Hutagalung R., Lwin K.M., Phyo A.P., Preechapornkul P., Imwong M., Pukrittayakamee S., Singhasivanon P., White N.J., Nosten F. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS ONE 2009, 4:e4551.
38. Cattamanchi A., Kyabayinze D., Hubbard A., Rosenthal P.J., Dorsey G. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am. J. Trop. Med. Hyg. 2003, 68:133-139.
39. Chaorattanakawee S., Tyner S.D., Lon C., Yingyuen K., Ruttvisutinunt W., Sundrakes S., Sai-gnam P., Johnson J.D., Walsh D.S., Saunders D.L., Lanteri C.A. Direct comparison of the histidine-rich protein-2 enzyme-linked immunosorbent assay (HRP-2 ELISA) and malaria SYBR green I fluorescence (MSF) drug sensitivity tests in Plasmodium falciparum reference clones and fresh ex vivo field isolates from Cambodia. Malaria J. 2013, 12:239.
40. Cheeseman I.H., Miller B.A., Nair S., Nkhoma S., Tan A., Tan J.C., Al Saai S., Phyo A.P., Moo C.L., Lwin K.M., McGready R., Ashley E., Imwong M., Stepniewska K., Yi P., Dondorp A.M., Mayxay M., Newton P.N., White N.J., Nosten F., Ferdig M.T., Anderson T.J. A major genome region underlying artemisinin resistance in malaria. Science 2012, 336:79-82.
41. 3H]hypoxanthine incorporation. Exp. Parasitol. 1983, 55:138-146.
42. Co E.M., Dennull R.A., Reinbold D.D., Waters N.C., Johnson J.D. Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria SYBR Green I-based fluorescence assay. Antimicrob. Agents Chemother. 2009, 53:2557-2563.
43. Collins W.J., Greenhouse B., Rosenthal P.J., Dorsey G. The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005. Malaria J. 2006, 5:122.
44. Conway D.J., Cavanagh D.R., Tanabe K., Roper C., Mikes Z.S., Sakihama N., Bojang K.A., Oduola A.M., Kremsner P.G., Arnot D.E., Greenwood B.M., McBride J.S. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat. Med. 2000, 6:689-692.
45. Corbett Y., Herrera L., Gonzalez J., Cubilla L., Capson T.L., Coley P.D., Kursar T.A., Romero L.I., Ortega-Barria E. A novel DNA-based microfluorimetric method to evaluate antimalarial drug activity. Am. J. Trop. Med. Hyg. 2004, 70:119-124.
46. Cowman A.F., Morry M.J., Biggs B.A., Cross G.A., Foote S.J. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:9109-9113.
47. Crameri A., Marfurt J., Mugittu K., Maire N., Regos A., Coppee J.Y., Sismeiro O., Burki R., Huber E., Laubscher D., Puijalon O., Genton B., Felger I., Beck H.P. Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with parasite resistance to antimalaria drugs. J. Clin. Microbiol. 2007, 45:3685-3691.
48. Daniels R., Ndiaye D., Wall M., McKinney J., Séne P.D., Sabeti P.C., Volkman S.K., Mboup S., Wirth D.F. Rapid, field-deployable method for genotyping and discovery of single-nucleotide polymorphisms associated with drug resistance in Plasmodium falciparum. Antimicrob. Agents Chemother. 2012, 56:2976.
49. D'Alessandro U. Antimalarial drug resistance: surveillance and molecular methods for national malaria control programmes. Mem. Inst. Osw. Cruz 1998, 93:627-630.
50. Decuypere S., Elinck E., Van Overmeir C., Talisuna A.O., D'Alessandro U., Dujardin J.-C. Pathogen genotyping in polyclonal infections: application of a fluorogenic polymerase-chain-reaction assay in malaria. J. Infect. Dis. 2003, 188:1245-1249.
51. de Monbrison F., Raynaud D., Latour-Fondanaiche C., Staal A., Favre S., Kaiser K., Peyron F., Picot S. Real-time PCR for chloroquine sensitivity assay and for pfmdr1-pfcrt single nucleotide polymorphisms in Plasmodium falciparum. J. Microbiol. Methods 2003, 54:391-401.
52. Desjardins R.E., Canfield C.J., Haynes J.D., Chulay J.D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 1979, 16:710-718.
53. Dieng T., Bah I.B., Ndiaye P.M., Diallo I., Diop B.M., Brasseur P., Mboup S., Wirth D., Ndir O. In vitro evaluation of the sensitivity of Plasmodium falciparum to chloroquine using the deli-microtest in region of Dakar, Senegal. Méd. Ttrop. (Mars) 2005, 65:580-583.
54. Djimdé A., Doumbo O.K., Cortese J.F., Kayentao K., Doumbo S., Diourte Y., Coulibaly D., Dicko A., Su X.Z., Nomura T., Fidock D.A., Wellems T.E., Plowe C.V. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 2001, 344:257-263.
55. Djimdé A., Doumbo O.K., Steketee R.W., Plowe C.V. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet 2001, 358:890-891.
56. Djimdé A.A., Dolo A., Ouattara A., Diakite S., Plowe C.V., Doumbo O.K. Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones. J. Infect. Dis. 2004, 190:853-855.
57. Djimdé A.A., Doumbo O.K., Traore O., Guindo A.B., Kayentao K., Diourte Y., Niare-Doumbo S., Coulibaly D., Kone A.K., Cissoko Y., Tekete M., Fofana B., Dicko A., Diallo D.A., Wellems T.E., Kwiatkowski D., Plowe C.V. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 2003, 69:558-563.
58. Dondorp A.M., Nosten F., Yi P., Das D., Phyo A.P., Tarning J., Lwin K.M., Ariey F., Hanpithakpong W., Lee S.J., Ringwald P., Silamut K., Imwong M., Chotivanich K., Lim P., Herdman T., An S.S., Yeung S., Singhasivanon P., Day N.P., Lindegardh N., Socheat D., White N.J. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 2009, 361:455-467.
59. Dorsey G., Njama D., Kamya M.R., Cattamanchi A., Kyabayinze D., Staedke S.G., Gasasira A., Rosenthal P.J. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 2002, 360:2031-2038.
60. Druilhe P., Moreno A., Blanc C., Brasseur P.H., Jacquier P. A colorimetric in vitro drug sensitivity assay for Plasmodium falciparum based on a highly sensitive double-site lactate dehydrogenase antigen-capture enzyme-linked immunosorbent assay. Am. J. Trop. Med. Hyg. 2001, 64:233-241.
61. Duraisingh M.T., Cowman A.F. Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Trop. 2005, 94:181-190.
62. Duraisingh M.T., Curtis J., Warhurst D.C. Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp. Parasitol. 1998, 89:1-8.
63. Durand R., Eslahpazire J., Jafari S., Delabre J.F., Marmorat-Khuong A., di Piazza J.P., Le Bras J. Use of molecular beacons to detect an antifolate resistance-associated mutation in Plasmodium falciparum. Antimicrob. Agents Chemother. 2000, 44:3461-3464.
64. Durand R., Huart V., Jafari S., Le Bras J. Rapid detection of a molecular marker for chloroquine-resistant falciparum malaria. Antimicrob. Agents Chemother. 2002, 46:2684-2686.
65. Eboumbou Moukoko E.C., Bogreau H., Briolant S., Pradines B., Rogier C. Molecular markers of Plasmodium falciparum drug resistance. Méd. Ttrop. (Mars) 2009, 69:606-612.
66. Ekland E.H., Fidock D.A. Advances in understanding the genetic basis of antimalarial drug resistance. Curr. Opin. Microbiol. 2007, 10:363-370.
67. Elabbadi N., Ancelin M.L., Vial H.J. Use of radioactive ethanolamine incorporation into phospholipids to assess in vitro antimalarial activity by the semiautomated microdilution technique. Antimicrob. Agents Chemother. 1992, 36:50-55.
68. Elbashir M.I., Adam I. Antimalarial drugs resistance in Sudan. Khar Med. J. 2008, 1:7-11.
69. Eldin de Pecoulas P., Basco L.K., Abdallah B., Dje M.K., Le Bras J., Mazabraud A. Plasmodium falciparum: detection of antifolate resistance by mutation-specific restriction enzyme digestion. Exp. Parasitol. 1995, 80:483-487.
70. Enosse S., Magnussen P., Abacassamo F., Gomez-Olive X., Ronn A.M., Thompson R., Alifrangis M. Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique. Malaria J. 2008, 7:115.
71. Escalante A.A., Lal A.A., Ayala F.J. Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. Genetics 1998, 149:189-202.
72. Farcas G.A., Soeller R., Zhong K., Zahirieh A., Kain K.C. Real-time polymerase chain reaction assay for the rapid detection and characterization of chloroquine-resistant Plasmodium falciparum malaria in returned travelers. Clin. Infect. Dis. 2006, 42:622-627.
73. Farnert A., Arez A.P., Babiker H.A., Beck H.P., Benito A., Bjorkman A., Bruce M.C., Conway D.J., Day K.P., Henning L., Mercereau-Puijalon O., Ranford-Cartwright L.C., Rubio J.M., Snounou G., Walliker D., Zwetyenga J., do Rosario V.E. Genotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study. Trans. R. Soc. Trop. Med. Hyg. 2001, 95:225-232.
74. Felger I., Tavul L., Beck H.P. Plasmodium falciparum: a rapid technique for genotyping the merozoite surface protein 2. Exp. Parasitol. 1993, 77:372-375.
75. Fidock D.A., Nomura T., Talley A.K., Cooper R.A., Dzekunov S.M., Ferdig M.T., Ursos L.M., Sidhu A.B., Naude B., Deitsch K.W., Su X.Z., Wootton J.C., Roepe P.D., Wellems T.E. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 2000, 6:861-871.
76. Flegg J.A., Guerin P.J., White N.J., Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malaria J. 2011, 10:339.
77. Foote S.J., Galatis D., Cowman A.F. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:3014-3017.
78. Frosch A.E., Venkatesan M., Laufer M.K. Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Malaria J. 2011, 10:116.
79. Gan L., Loh J. Rapid identification of chloroquine and atovaquone drug resistance in Plasmodium falciparum using high-resolution melt-polymerase chain reaction. Malaria J. 2010, 9:134.
80. Gatton M.L., Cheng Q. Can estimates of antimalarial efficacy from field studies be improved?. Trends Parasitol. 2008, 24:68-73.
81. Gharbi M., Flegg J.A., Hubert V., Kendjo E., Metcalf J.E., Bertaux L., Guerin P.J., Le Bras J., Aboubaca A., Agnamey P., Angoulvant A., Barbut P., Basset D., Belkadi G., Bellanger A.P., Bemba D., Benoit-Vica F., Berry A., Bigel M.L., Bonhomme J., Botterel F., Bouchaud O., Bougnoux M.E., Bouree P., Bourgeois N., Branger C., Bret L., Buret B., Casalino E., Chevrier S., Conquere de Monbrison F., Cuisenier B., Danis M., Darde M.L., De Gentile L., Delarbre J.M., Delaunay P., Delaval A., Desoubeaux G., Develoux M., Dunand J., Durand R., Eloy O., Fauchet N., Faugere B., Faye A., Fenneteau O., Flori P., Fontrouge M., Garabedian C., Gayandrieu F., Godineau N., Houze P., Houze S., Hurst J.P., Ichou H., Lachaud L., Lebuisson A., Lefevre M., LeGuern A.S., Le Moal G., Lusina D., Machouart M.C., Malvy D., Matheron S., Maubon D., Mechali D., Megarbane B., Menard G., Millon L., Aiach M.M., Minodier P., Morelle C., Nevez G., Parola P., Parzy D., Patey O., Patoz P., Penn P., Perignon A., Picot S., Pilo J.E., Poilane I., Pons D., Poupart M., Pradines B., Raffenot D., Rapp C., Receveur M.C., Sarfati C., Senghor Y., Simon F., Siriez J.Y., Taudon N., Thellier M., Thouvenin M., Toubas D. Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000-2011. Malaria J. 2013, 12:35.
82. Greenhouse B., Dokomajilar C., Hubbard A., Rosenthal P.J., Dorsey G. Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials. Antimicrob. Agents Chemother. 2007, 51:3096-3103.
83. Guerra C.A., Hay S.I., Lucioparedes L.S., Gikandi P.W., Tatem A.J., Noor A.M., Snow R.W. Assembling a global database of malaria parasite prevalence for the Malaria Atlas Project. Malaria J. 2007, 6:17.
84. Guthmann J.P., Pinoges L., Checchi F., Cousens S., Balkan S., van Herp M., Legros D., Olliaro P. Methodological issues in the assessment of antimalarial drug treatment: analysis of 13 studies in eight African countries from 2001 to 2004. Antimicrob. Agents Chemother. 2006, 50:3734-3739.
85. Gyang F.N., Peterson D.S., Wellems T.E. Plasmodium falciparum: rapid detection of dihydrofolate reductase mutations that confer resistance to cycloguanil and pyrimethamine. Exp. Parasitol. 1992, 74:470-472.
86. Hastings I.M. Molecular markers as indicators of antimalarial drug failure rates. Trop. Med. Int. Health 2007, 12:1298-1301.
87. Hastings I.M., Watkins W.M., White N.J. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2002, 357:505-519.
88. Hayton K., Su X.Z. Genetic and biochemical aspects of drug resistance in malaria parasites. Curr. Drug Targets Infect. Disord. 2004, 4:1-10.
89. Hedt B.L., Laufer M.K., Cohen T. Drug resistance surveillance in resource-poor settings: current methods and considerations for TB, HIV, and malaria. Am. J. Trop. Med. Hyg. 2011, 84:192-199.
90. Hughes A.L. Positive selection and interallelic recombination at the merozoite surface antigen-1 (MSA-1) locus of Plasmodium falciparum. Mol. Biol. Evol. 1992, 9:381-393.
91. Hughes M.K., Hughes A.L. Natural selection on Plasmodium surface proteins. Mol. Biochem. Parasitol. 1995, 71:99-113.
92. Hyde J.E. Drug-resistant malaria. Trends Parasitol. 2005, 21:494-498.
93. Ibrahim M.L., Steenkeste N., Khim N., Adam H.H., Konate L., Coppee J.Y., Ariey F., Duchemin J.B. Field-based evidence of fast and global increase of Plasmodium falciparum drug-resistance by DNA-microarrays and PCR/RFLP in Niger. Malaria J. 2009, 8:32.
94. Imwong M., Dondorp A.M., Nosten F., Yi P., Mungthin M., Hanchana S., Das D., Phyo A.P., Lwin K.M., Pukrittayakamee S., Lee S.J., Saisung S., Koecharoen K., Nguon C., Day N.P., Socheat D., White N.J. Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob. Agents Chemother. 2010, 54:2886-2892.
95. Imwong M., Snounou G., Pukrittayakamee S., Tanomsing N., Kim J.R., Nandy A., Guthmann J.P., Nosten F., Carlton J., Looareesuwan S., Nair S., Sudimack D., Day N.P., Anderson T.J., White N.J. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J. Infect. Dis. 2007, 195:927-933.
96. Iriemenam N.C., Shah M., Gatei W., van Eijk A.M., Ayisi J., Kariuki S., Vanden Eng J., Owino S.O., Lal A.A., Omosun Y.O., Otieno K., Desai M., ter Kuile F.O., Nahlen B., Moore J., Hamel M.J., Ouma P., Slutsker L., Shi Y.P. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Malaria J. 2012, 11:134.
97. Jambou R., Legrand E., Niang M., Khim N., Lim P., Volney B., Ekala M.T., Bouchier C., Esterre P., Fandeur T., Mercereau-Puijalon O. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005, 366:1960-1963.
98. Johnson J.D., Dennull R.A., Gerena L., Lopez-Sanchez M., Roncal N.E., Waters N.C. Assessment and continued validation of the malaria SYBR Green I-based fluorescence assay for use in malaria drug screening. Antimicrob. Agents Chemother. 2007, 51:1926-1933.
99. Kaddouri H., Nakache S., Houze S., Mentre F., Le Bras J. Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from Africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob. Agents Chemother. 2006, 50:3343-3349.
100. Karl S., Wong R.P., St Pierre T.G., Davis T.M. A comparative study of a flow-cytometry-based assessment of in vitro Plasmodium falciparum drug sensitivity. Malaria J. 2009, 8:294.
101. Khattak A.A., Venkatesan M., Jacob C.G., Artimovich E.M., Nadeem M.F., Nighat F., Hombhanje F., Mita T., Malik S.A., Plowe C.V. A comprehensive survey of polymorphisms conferring anti-malarial resistance in Plasmodium falciparum across Pakistan. Malaria J. 2013, 12:300.
102. Kublin J.G., Cortese J.F., Njunju E.M., Mukadam R.A., Wirima J.J., Kazembe P.N., Djimdé A.A., Kouriba B., Taylor T.E., Plowe C.V. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J. Infect. Dis. 2003, 187:1870-1875.
103. Kublin J.G., Dzinjalamala F.K., Kamwendo D.D., Malkin E.M., Cortese J.F., Martino L.M., Mukadam R.A., Rogerson S.J., Lescano A.G., Molyneux M.E., Winstanley P.A., Chimpeni P., Taylor T.E., Plowe C.V. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 2002, 185:380-388.
104. Laufer M.K. Monitoring antimalarial drug efficacy: current challenges. Curr. Infect. Dis. Rep. 2009, 11:59-65.
105. Laufer M.K., Djimdé A.A., Plowe C.V. Monitoring and deterring drug-resistant malaria in the era of combination therapy. Am. J. Trop. Med. Hyg. 2007, 77:160-169.
106. Laufer M.K., Plowe C.V. Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies. Drug Resist. Updat. 2004, 7:279-288.
107. Laufer M.K., Thesing P.C., Eddington N.D., Masonga R., Dzinjalamala F.K., Takala S.L., Taylor T.E., Plowe C.V. Return of chloroquine antimalarial efficacy in Malawi. N. Engl. J. Med. 2006, 355:1959-1966.
108. LeClair N.P., Conard M.D., Baliraine F.N., Nsanzabana C., Nsobya S.L., Rosenthal P.J. Optimization of a ligase detection reaction-fluorescent microsphere assay for characterization of resistance-mediating polymorphisms in African samples of Plasmodium falciparum. J. Clin. Microbiol. 2013, 51:2564-2570.
109. Lin J.T., Juliano J.J., Wongsrichanalai C. Drug-resistant malaria: the era of ACT. Curr. Infect. Dis. Rep. 2010, 12:165-173.
110. Magesa S.M., Mdira K.Y., Farnert A., Simonsen P.E., Bygbjerg I.C., Jakobsen P.H. Distinguishing Plasmodium falciparum treatment failures from re-infections by using polymerase chain reaction genotyping in a holoendemic area in northeastern Tanzania. Am. J. Trop. Med. Hyg. 2001, 65:477-483.
111. Makler M.T., Ries J.M., Williams J.A., Bancroft J.E., Piper R.C., Gibbins B.L., Hinrichs D.J. Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity. Am. J. Trop. Med. Hyg. 1993, 48:739-741.
112. Mang'era C.M., Mbai F.N., Omedo I.A., Mireji P.O., Omar S.A. Changes in genotypes of Plasmodium falciparum human malaria parasite following withdrawal of chloroquine in Tiwi, Kenya. Acta Trop. 2012, 123:202-207.
113. Marfurt J., Muller I., Sie A., Oa O., Reeder J.C., Smith T.A., Beck H.P., Genton B. The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea. Malaria J. 2008, 7:61.
114. Marfurt J., Smith T.A., Hastings I.M., Muller I., Sie A., Oa O., Baisor M., Reeder J.C., Beck H.P., Genton B. Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance. Malaria J. 2010, 9:8.
115. Mayxay M., Chotivanich K., Pukrittayakamee S., Newton P., Looareesuwan S., White N.J. Contribution of humoral immunity to the therapeutic response in falciparum malaria. Am. J. Trop. Med. Hyg. 2001, 65:918-923.
116. McCollum A.M., Schneider K.A., Griffing S.M., Zhou Z., Kariuki S., Ter-Kuile F., Shi Y.P., Slutsker L., Lal A.A., Udhayakumar V., Escalante A.A. Differences in selective pressure on dhps and dhfr drug resistant mutations in western Kenya. Malaria J. 2012, 11:77.
117. Mita T., Kaneko A., Lum J.K., Bwijo B., Takechi M., Zungu I.L., Tsukahara T., Tanabe K., Kobayakawa T., Bjorkman A. Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am. J. Trop. Med. Hyg. 2003, 68:413-415.
118. Mok S., Imwong M., Mackinnon M.J., Sim J., Ramadoss R., Yi P., Mayxay M., Chotivanich K., Liong K.Y., Russell B., Socheat D., Newton P.N., Day N.P., White N.J., Preiser P.R., Nosten F., Dondorp A.M., Bozdech Z. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics 2011, 12:391.
119. Moreno A., Brasseur P., Cuzin-Ouattara N., Blanc C., Druilhe P. Evaluation under field conditions of the colourimetric DELI-microtest for the assessment of Plasmodium falciparum drug resistance. Trans. R. Soc. Trop. Med. Hyg. 2001, 95:100-103.
120. Mugittu K., Adjuik M., Snounou G., Ntoumi F., Taylor W., Mshinda H., Olliaro P., Beck H.P. Molecular genotyping to distinguish between recrudescents and new infections in treatment trials of Plasmodium falciparum malaria conducted in Sub-Saharan Africa: adjustment of parasitological outcomes and assessment of genotyping effectiveness. Trop. Med. Int. Health 2006, 11:1350-1359.
121. Mugittu K.N. Plasmodium falciparum drug resistance, molecular genotyping and generation of a malaria resistance genogram by DNA microarray-based technology 2006, University of Basel, Basel.
122. Mutabingwa T.K., Malle L.N., Mtui S.N. Chloroquine therapy still useful in the management of malaria during pregnancy in Muheza, Tanzania. Trop. Geogr. Med. 1991, 34:131-135.
123. Mwai L., Ochong E., Abdirahman A., Kiara S.M., Ward S., Kokwaro G., Sasi P., Marsh K., Borrmann S., Mackinnon M., Nzila A. Chloroquine resistance before and after its withdrawal in Kenya. Malaria J. 2009, 8:106.
124. Mwangi J.M., Omar S.A., Ranford-Cartwright L.C. Comparison of microsatellite and antigen-coding loci for differentiating recrudescing Plasmodium falciparum infections from reinfections in Kenya. Int. J. Parasitol. 2006, 36:329-336.
125. Nankoberanyi S., Mbogo G.W., LeClair N.P., Conard M.D., Tumwebaze P., Tukwasibwe S., Kamya M.R., Tappero J., Nsobya S.L., Rosenthal P.J. Validation of the ligase detection reaction fluoresecnt microsphere assay for the detection of Plasmodium falciparum resistance mediating polymorphisms in Uganda. Malaria J. 2014, 13:95.
126. Ndiaye D., Patel V., Demas A., LeRoux M., Ndir O., Mboup S., Clardy J., Lakshmanan V., Daily J.P., Wirth D.F. A non-radioactive DAPI-based high-throughput in vitro assay to assess Plasmodium falciparum responsiveness to antimalarials - increased sensitivity of P. falciparum to chloroquine in Senegal. Am. J. Trop. Med. Hyg. 2010, 82:228-230.
127. Nelson A.L., Purfield A., McDaniel P., Uthaimongkol N., Buathong N., Sriwichai S., Miller R.S., Wongsrichanalai C., Meshnick S.R. pfmdr1 genotyping and in vivo mefloquine resistance on the Thai-Myanmar border. Am. J. Trop. Med. Hyg. 2005, 72:586-592.
128. Nguyen-Dinh P., Payne D. Pyrimethamine sensitivity in Plasmodium falciparum: determination in vitro by a modified 48-hour test. Bull. World Health Organ. 1980, 58:909-912.
129. Nguyen-Dinh P., Trager W. Plasmodium falciparum in vitro: determination of chloroquine sensitivity of three new strains by a modified 48-hour test. Am. J. Trop. Med. Hyg. 1980, 29:339-342.
130. Noedl H., Attlmayr B., Wernsdorfer W.H., Kollaritsch H., Miller R.S. A histidine-rich protein 2-based malaria drug sensitivity assay for field use. Am. J. Trop. Med. Hyg. 2004, 71:711-714.
131. Noedl H., Bronnert J., Yingyuen K., Attlmayr B., Kollaritsch H., Fukuda M. Simple histidine-rich protein 2 double-site sandwich enzyme-linked immunosorbent assay for use in malaria drug sensitivity testing. Antimicrob. Agents Chemother. 2005, 49:3575-3577.
132. Noedl H., Se Y., Schaecher K., Smith B.L., Socheat D., Fukuda M.M. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 2008, 359:2619-2620.
133. Noedl H., Wernsdorfer W.H., Miller R.S., Wongsrichanalai C. Histidine-rich protein II: a novel approach to malaria drug sensitivity testing. Antimicrob. Agents Chemother. 2002, 46:1658-1664.
134. Noedl H., Wongsrichanalai C., Wernsdorfer W.H. Malaria drug-sensitivity testing: new assays, new perspectives. Trends Parasitol. 2003, 19:175-181.
135. Nyachieo A.C., Laurent V.A.N.O., Dujardin T., D'Alessandro J.C.U. Plasmodium falciparum genotyping by microsatellites as a method to distinguish between recrudescent and new infections. Am. J. Trop. Med. Hyg. 2005, 73:210-213.
136. Nzila A.M., Nduati E., Mberu E.K., Sibley C.H., Monks S.A., Winstanley P.A., Watkins W.M. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J. Infect. Dis. 2000, 181:2023-2028.
137. Ochong E., Tumwebaze P.K., Byaruhanga O., Greenhouse B., Rosenthal P.J. Fitness consequences of Plasmodium falciparum pfmdr1 polymorphisms inferred from ex vivo culture of Ugandan parasites. Antimicrob. Agents Chemother. 2013.
138. Ohrt C., Purnomo, Sutamihardja M.A., Tang D., Kain K.C. Impact of microscopy error on estimates of protective efficacy in malaria-prevention trials. J. Infect. Dis. 2002, 186:540-546.
139. Parzy D., Doerig C., Pradines B., Rico A., Fusai T., Doury J.C. Proguanil resistance in Plasmodium falciparum African isolates: assessment by mutation-specific polymerase chain reaction and in vitro susceptibility testing. Am. J. Trop. Med. Hyg. 1997, 57:646-650.
140. Pascual A., Parola P., Benoit-Vical F., Simon F., Malvy D., Picot S., Delaunay P., Basset D., Maubon D., Faugere B., Menard G., Bourgeois N., Oeuvray C., Didillon E., Rogier C., Pradines B. Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum. Malaria J. 2012, 11:45.
141. Pattanapanyasat K., Thaithong S., Kyle D.E., Udomsangpetch R., Yongvanitchit K., Hider R.C., Webster H.K. Flow cytometric assessment of hydroxypyridinone iron chelators on in vitro growth of drug-resistant malaria. Cytometry 1997, 27:84-91.
142. Pearce R.J., Drakeley C., Chandramohan D., Mosha F., Roper C. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrob. Agents Chemother. 2003, 47:1347-1354.
143. Petersen I., Eastman R., Lanzer M. Drug-resistant malaria: molecular mechanisms and implications for public health. FEBS Lett. 2011, 585:1551-1562.
144. Peterson D.S., Di Santi S.M., Povoa M., Calvosa V.S., Do Rosario V.E., Wellems T.E. Prevalence of the dihydrofolate reductase Asn-108 mutation as the basis for pyrimethamine-resistant falciparum malaria in the Brazilian Amazon. Am. J. Trop. Med. Hyg. 1991, 45:492-497.
145. Peterson D.S., Walliker D., Wellems T.E. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:9114-9118.
146. Pickard A.L., Wongsrichanalai C., Purfield A., Kamwendo D., Emery K., Zalewski C., Kawamoto F., Miller R.S., Meshnick S.R. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob. Agents Chemother. 2003, 47:2418-2423.
147. Picot S., Olliaro P., de Monbrison F., Bienvenu A.-L., Price R.N., Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malaria J. 2009, 8:89.
148. Pillai D., Lau R., Khairnar K., Lepore R., Via A., Staines H., Krishna S. Artemether resistance in vitro is linked to mutations in PfATP6 that also interact with mutations in PfMDR1 in travellers returning with Plasmodium falciparum infections. Malaria J. 2012, 11:131.
149. Plowe C.V. Monitoring antimalarial drug resistance: making the most of the tools at hand. J. Exp. Biol. 2003, 206:3745-3752.
150. Plowe C.V. Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. Curr. Top. Microbiol. Immunol. 2005, 295:55-79.
151. Plowe C.V., Cortese J.F., Djimdé A., Nwanyanwu O.C., Watkins W.M., Winstanley P.A., Estrada-Franco J.G., Mollinedo R.E., Avila J.C., Cespedes J.L., Carter D., Doumbo O.K. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J. Infect. Dis. 1997, 176:1590-1596.
152. Plowe C.V., Djimdé A., Bouare M., Doumbo O., Wellems T.E. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am. J. Trop. Med. Hyg. 1995, 52:565-568.
153. Plowe C.V., Roper C., Barnwell J.W., Happi C.T., Joshi H.H., Mbacham W., Meshnick S.R., Mugittu K., Naidoo I., Price R.N., Shafer R.W., Sibley C.H., Sutherland C.J., Zimmerman P.A., Rosenthal P.J. World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malaria J. 2007, 6:121.
154. Prasad R.N., Prasad H., Virk K.J., Sharma V.P. Application of a simplified in-vivo test system for determining chloroquine resistance in Plasmodium falciparum. Bull. World Health Organ. 1990, 68:755-758.
155. Pratt-Riccio L.R., Chehuan Y.F., Siqueira M.J., das Gracas Alecrim M., Bianco-Junior C., Druilhe P., Brasseur P., de Fatima Ferreira-da-Cruz M., Carvalho L.J., Daniel-Ribeiro C.T. Use of a colorimetric (DELI) test for the evaluation of chemoresistance of Plasmodium falciparum and Plasmodium vivax to commonly used anti-plasmodial drugs in the Brazilian Amazon. Malaria J. 2013, 12:281.
156. Prescott N., Stowers A.W., Cheng Q., Bobogare A., Rzepczyk C.M., Saul A. Plasmodium falciparum genetic diversity can be characterised using the polymorphic merozoite surface antigen 2 (MSA-2) gene as a single locus marker. Mol. Biochem. Parasitol. 1994, 63:203-212.
157. Price R.N., Nosten F., Simpson J.A., Luxemburger C., Phaipun L., ter Kuile F., van Vugt M., Chongsuphajaisiddhi T., White N.J. Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am. J. Trop. Med. Hyg. 1999, 60:1019-1023.
158. Price R.N., Dorsey G., Ashley E.A., Barnes K.I., Baird J.K., d'Alessandro U., Guerin P.J., Laufer M.K., Naidoo I., Nosten F., Olliaro P., Plowe C.V., Ringwald P., Sibley C.H., Stepniewska K., White N.J. World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs. Malaria J. 2007, 6:119.
159. Price R.N., Uhlemann A.C., Brockman A., McGready R., Ashley E., Phaipun L., Patel R., Laing K., Looareesuwan S., White N.J., Nosten F., Krishna S. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004, 364:438-447.
160. Price R.N., Uhlemann A.C., van Vugt M., Brockman A., Hutagalung R., Nair S., Nash D., Singhasivanon P., Anderson T.J., Krishna S., White N.J., Nosten F. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin. Infect. Dis. 2006, 42:1570-1577.
161. Prokopev D.I. Resistance of Malaria Parasites to Drugs. Report of a WHO Scientific Group. World Health Organization Technical Report Series 296 1965, 1-65.
162. Purfield A., Nelson A., Laoboonchai A., Congpuong K., McDaniel P., Miller R.S., Welch K., Wongsrichanalai C., Meshnick S.R. A new method for detection of pfmdr1 mutations in Plasmodium falciparum DNA using real-time PCR. Malaria J. 2004, 3:9.
163. Ranford-Cartwright L.C., Johnston K.L., Abdel-Muhsin A.M., Khan B.K., Babiker H.A. Critical comparison of molecular genotyping methods for detection of drug-resistant Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. 2002, 96:568-572.
164. Rason M.A., Randriantsoa T., Andrianantenaina H., Ratsimbasoa A., Menard D. Performance and reliability of the SYBR Green I based assay for the routine monitoring of susceptibility of Plasmodium falciparum clinical isolates. Trans. R. Soc. Trop. Med. Hyg. 2008, 102:346-351.
165. Reed M.B., Saliba K.J., Caruana S.R., Kirk K., Cowman A.F. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000, 403:906-909.
166. Richards W.H., Maples B.K. Studies on Plasmodium falciparum in continuous cultivation, I. The effect of chloroquine and pyrimethamine on parasite growth and viability. Ann. Trop. Med. Parasitol. 1979, 73:99-108.
167. Rieckmann K.H., Campbell G.H., Sax L.J., Mrema J.E. Drug sensitivity of Plasmodium falciparum. An in-vitro microtechnique. Lancet 1978, 1:22-23.
168. Rieckmann K.H., McNamara J.V., Frischer H., Stockert T.A., Carson P.E., Powell R.D. Effects of chloroquine, quinine, and cycloguanil upon the maturation of asexual erythrocytic forms of two strains of Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 1968, 17:661-671.
169. Ringwald P., Basco L.K. Comparison of in vivo and in vitro tests of resistance in patients treated with chloroquine in Yaounde, Cameroon. Bull. World Health Org. 1999, 77:34-43.
170. Russell B., Malleret B., Suwanarusk R., Anthony C., Kanlaya S., Lau Y.L., Woodrow C.J., Nosten F., Renia L. Field-based flow cytometry for ex vivo characterization of Plasmodium vivax and P. falciparum antimalarial sensitivity. Antimicrob. Agents Chemother. 2013, 57:5170-5174.
171. Sibley C.H., Barnes K.I., Plowe C.V. The rationale and plan for creating a World Antimalarial Resistance Network (WARN). Malaria J. 2007, 6:118.
172. Sibley C.H., Barnes K.I., Watkins W.M., Plowe C.V. A network to monitor antimalarial drug resistance: a plan for moving forward. Trends Parasitol. 2008, 24:43-48.
173. Sibley C.H., Hyde J.E., Sims P.F., Plowe C.V., Kublin J.G., Mberu E.K., Cowman A.F., Winstanley P.A., Watkins W.M., Nzila A.M. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?. Trends Parasitol. 2001, 17:582-588.
174. Sibley C., Price R.N. Monitoring antimalarial drug resistance: applying lessons learned from the past in a fast-moving present. Int. J. Parasitol.: Drugs Drug Resist. 2012, 2:126-133.
175. Sibley C.H., Ringwald P. A database of antimalarial drug resistance. Malaria J. 2006, 5:48.
176. Slater M., Kiggundu M., Dokomajilar C., Kamya M.R., Bakyaita N., Talisuna A., Rosenthal P.J., Dorsey G. Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. Am. J. Trop. Med. Hyg. 2005, 73:256-262.
177. Smilkstein M., Sriwilaijaroen N., Kelly J.X., Wilairat P., Riscoe M. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother. 2004, 48:1803-1806.
178. Snewin V.A., Herrera M., Sanchez G., Scherf A., Langsley G., Herrera S. Polymorphism of the alleles of the merozoite surface antigens MSA1 and MSA2 in Plasmodium falciparum wild isolates from Colombia. Mol. Biochem. Parasitol. 1991, 49:265-275.
179. Snounou G. Genotyping of Plasmodium spp. nested PCR. Methods Mol. Med. 2002, 72:103-116.
180. Snounou G., Beck H.P. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol. Today 1998, 14:462-467.
181. Sowunmi A., Fateye B.A., Adedeji A.A., Fehintola F.A., Happi T.C. Risk factors for gametocyte carriage in uncomplicated falciparum malaria in children. Parasitology 2004, 129:255-262.
182. Steenkeste N., Dillies M.A., Khim N., Sismeiro O., Chy S., Lim P., Crameri A., Bouchier C., Mercereau-Puijalon O., Beck H.P., Imwong M., Dondorp A.M., Socheat D., Rogier C., Coppee J.Y., Ariey F. FlexiChip package: an universal microarray with a dedicated analysis software for high-throughput SNPs detection linked to anti-malarial drug resistance. Malaria J. 2009, 8:229.
183. 50 values using a Bayesian approach. Malaria J. 2007, 6:4.
184. Stepniewska K., Price R.N., Sutherland C.J., Drakeley C.J., von Seidlein L., Nosten F., White N.J. Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity. Malaria J. 2008, 7:249.
185. Stepniewska K., Taylor W.R., Mayxay M., Price R., Smithuis F., Guthmann J.P., Barnes K., Myint H.Y., Adjuik M., Olliaro P., Pukrittayakamee S., Looareesuwan S., Hien T.T., Farrar J., Nosten F., Day N.P., White N.J. In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob. Agents Chemother. 2004, 48:4271-4280.
186. Stepniewska K., White N.J. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malaria J. 2006, 5:127.
187. Su X., Wellems T.E. Toward a high-resolution Plasmodium falciparum linkage map: polymorphic markers from hundreds of simple sequence repeats. Genomics 1996, 33:430-444.
188. Sulo J., Chimpeni P., Hatcher J., Kublin J.G., Plowe C.V., Molyneux M.E., Marsh K., Taylor T.E., Watkins W.M., Winstanley P.A. Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet 2002, 360:1136-1143.
189. Sutherland C.J., Alloueche A., Curtis J., Drakeley C.J., Ord R., Duraisingh M., Greenwood B.M., Pinder M., Warhurst D., Targett G.A. Gambian children successfully treated with chloroquine can harbor and transmit Plasmodium falciparum gametocytes carrying resistance genes. Am. J. Trop. Med. Hyg. 2002, 67:578-585.
190. Takala-Harrison S., Clark T.G., Jacob C.G., Cummings M.P., Miotto O., Dondorp A.M., Fukuda M.M., Nosten F., Noedl H., Imwong M., Bethell D., Se Y., Lon C., Tyner S.D., Saunders D.L., Socheat D., Ariey F., Phyo A.P., Starzengruber P., Fuehrer H.P., Swoboda P., Stepniewska K., Flegg J., Arze C., Cerqueira G.C., Silva J.C., Ricklefs S.M., Porcella S.F., Stephens R.M., Adams M., Kenefic L.J., Campino S., Auburn S., MacInnis B., Kwiatkowski D.P., Su X.Z., White N.J., Ringwald P., Plowe C.V. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:240-245.
191. Talisuna A.O., Bloland P., D'Alessandro U. History, dynamics, and public health importance of malaria parasite resistance. Clin. Microbiol. Rev. 2004, 17:235-254.
192. Trape J.F., Pison G., Preziosi M.P., Enel C., Desgrees du Lou A., Delaunay V., Samb B., Lagarde E., Molez J.F., Simondon F. Impact of chloroquine resistance on malaria mortality. C. R. Acad. Sci. Sér. III, Sci. 1998, 321:689-697.
193. Triglia T., Menting J.G., Wilson C., Cowman A.F. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13944-13949.
194. Tyner S.D., Lon C., Se Y., Bethell D., Socheat D., Noedl H., Sea D., Satimai W., Schaecher K., Rutvisuttinunt W., Fukuda M.M., Chaorattanakawee S., Yingyuen K., Sundrakes S., Chaichana P., Saingam P., Buathong N., Sriwichai S., Chann S., Timmermans A., Saunders D.L., Walsh D.S. Ex vivo drug sensitivity profiles of Plasmodium falciparum field isolates from Cambodia and Thailand, 2005 to 2010, determined by a histidine-rich protein-2 assay. Malaria J. 2012, 11:198.
195. van Vianen P.H., Thaithong S., Reinders P.P., van Engen A., van der Keur M., Tanke H.J., van der Kaay H.J., Mons B. Automated flow cytometric analysis of drug susceptibility of malaria parasites. Am. J. Trop. Med. Hyg. 1990, 43:602-607.
196. Veiga M.I., Ferreira P.E., Bjorkman A., Gil J.P. Multiplex PCR-RFLP methods for pfcrt, pfmdr1 and pfdhfr mutations in Plasmodium falciparum. Mol. Cell. Probes 2006, 20:100-104.
197. Vestergaard L.S., Ringwald P. Responding to the challenge of antimalarial drug resistance by routine monitoring to update national malaria treatment policies. Am. J. Trop. Med. Hyg. 2007, 77:153-159.
198. Viriyakosol S., Siripoon N., Petcharapirat C., Petcharapirat P., Jarra W., Thaithong S., Brown K.N., Snounou G. Genotyping of Plasmodium falciparum isolates by the polymerase chain reaction and potential uses in epidemiological studies. Bull. World Health Organ. 1995, 73:85-95.
199. Volkman S.K., Ndiaye D., Diakite M., Koita O.A., Nwakanma D., Daniels R.F., Park D.J., Neafsey D.E., Muskavitch M.A., Krogstad D.J., Sabeti P.C., Hartl D.L., Wirth D.F. Application of genomics to field investigations of malaria by the international centers of excellence for malaria research. Acta Trop. 2012, 121:324-332.
200. Wang P., Read M., Sims P.F., Hyde J.E. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol. Microbiol. 1997, 23:979-986.
201. Wang X., Mu J., Li G., Chen P., Guo X., Fu L., Chen L., Su X., Wellems T.E. Decreased prevalence of the Plasmodium falciparum chloroquine resistance transporter 76T marker associated with cessation of chloroquine use against P. falciparum malaria in Hainan, People's Republic of China. Am. J. Trop. Med. Hyg. 2005, 72:410-414.
202. Wellems T.E., Plowe C.V. Chloroquine-resistant malaria. J. Infect. Dis. 2001, 184:770-776.
203. Wernsdorfer W.H. Field evaluation of drug resistance in malaria. In vitro micro-test. Acta Trop. 1980, 37:222-227.
204. Wernsdorfer W.H., Payne D. Drug sensitivity tests in malaria parasites. Malaria. Principles and Practice of Malariology 1988, 1765-1800. Churchill Livingstone, Edinburgh. W.H. Wernsdorfer, I. McGregor (Eds.).
205. White N.J. The assessment of antimalarial drug efficacy. Trends Parasitol. 2002, 18:458-464.
206. White N.J. The parasite clearance curve. Malaria J. 2011, 10:278.
207. WHO Expert Committee on Malaria WHO Expert Committee on Malaria: Twentieth Report 2000, WHO, Geneva.
208. WHO Chemotherapy of malaria. Report of a WHO Scientific Group. WHO Tech Rep Ser. 1967.
209. WHO Chemotherapy of malaria and resistance to antimalarials Report of a WHO Scientific Group. WHO Technical Report Series, No. 529 1973, World Health Organization, Geneva.
210. WHO Practical Chemotherapy of Malaria: Report of a WHO Scientific Group. WHO Technical Report Series, No. 805 1990, World Health Organization, Geneva.
211. WHO In vitro m Micro-test (Mark II) for the 1990, World Health Organization, Geneva.
212. WHO Assessment of Therapeutic Efficacy of Antimalarial Drugs for Uncomplicated Falciparum Malaria in Areas with Intense Transmission 1996, World Health Organization, Geneva.
213. WHO In vitro micro-test (Mark II) for the assessment of the response of Plasmodium falciparum to chloroquine, mefloquine, quinine, sulfadoxine/pyrimethamine and amodiaquine 2001, World Health organization, Geneva.
214. WHO Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria 2003, World Health Organization, Geneva.
215. WHO Susceptibility of Plasmodium falciparum to antimalarial drugs: report on global monitoring: 1996-2004 2005, World Health Organization, Geneva.
216. WHO Guidelines for the treatment of malaria 2006, World Health Organization, Geneva.
217. WHO Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations 2008, World Health Organization, Geneva.
218. WHO Methods for surveillance of antimalarial drug efficacy 2009, World Health Organization, Geneva.
219. WHO Global report on antimalarial efficacy and drug resistance: 2000-2010 2010, World Health Organization, Geneva.
220. WHO Guidelines for treatment of malaria 2010, World Health Organization, Geneva.
221. WHO World malaria report 2011 2011, World Health Organization, Geneva.
222. Wilson P.E., Kazadi W., Kamwendo D.D., Mwapasa V., Purfield A., Meshnick S.R. Prevalence of pfcrt mutations in Congolese and Malawian Plasmodium falciparum isolates as determined by a new Taqman assay. Acta Trop. 2005, 93:97-106.
223. Witkowski B., Amaratunga C., Khim N., Sreng S., Chim P., Kim S., Lim P., Mao S., Sopha C., Sam B., Anderson J.M., Duong S., Chuor C.M., Taylor W.R., Suon S., Mercereau-Puijalon O., Fairhurst R.M., Menard D. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect. Dis. 2013, 13:1043-1049.
224. Wong R.P., Karunajeewa H., Mueller I., Siba P., Zimmerman P.A., Davis T.M. Molecular assessment of Plasmodium falciparum resistance to antimalarial drugs in Papua New Guinea using an extended ligase detection reaction fluorescent microsphere assay. Antimicrob. Agents Chemother. 2011, 55:798-805.
225. Wongsrichanalai C., Pickard A.L., Wernsdorfer W.H., Meshnick S.R. Epidemiology of drug-resistant malaria. Lancet Infect. Dis. 2002, 2:209-218.
226. Wooden J., Gould E.E., Paull A.T., Sibley C.H. Plasmodium falciparum: a simple polymerase chain reaction method for differentiating strains. Exp. Parasitol. 1992, 75:207-212.
227. Wu Y., Fairfield A.S., Oduola A., Cypess R.H. The Malaria Research and Reference Reagent Resource (MR4) Center - creating African opportunities. Afr. J. Med. Med. Sci. 2001, 30(Suppl.):52-54.
228. Zhang G.Q., Guan Y.Y., Sheng H.H., Zheng B., Wu S., Xiao H.S., Tang L.H. Multiplex PCR and oligonucleotide microarray for detection of single-nucleotide polymorphisms associated with Plasmodium falciparum drug resistance. J. Clin. Microbiol. 2008, 46:2167-2174.
229. Zhou Z., Poe A.C., Limor J., Grady K.K., Goldman I., McCollum A.M., Escalante A.A., Barnwell J.W., Udhayakumar V. Pyrosequencing, a high-throughput method for detecting single nucleotide polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum. J. Clin. Microbiol. 2006, 44:3900-3910.
230. Zhu X., Snounou G., Jarra W., Thaithong S., Brown K.N. Genotyping of Plasmodium falciparum isolates by amplification of glutamate-rich protein gene using polymerase chain reaction. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 1998, 16:331-334.
231. Zindrou S., Dao L.D., Xuyen P.T., Dung N.P., Sy N.D., Skold O., Swedberg G. Rapid detection of pyrimethamine susceptibility of Plasmodium falciparum by restriction endonuclease digestion of the dihydrofolate reductase gene. Am. J. Trop. Med. Hyg. 1996, 54:185-188.
232. Zolg J.W., Plitt J.R., Chen G.X., Palmer S. Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol. Biochem. Parasitol. 1989, 36:253-262.